Phase Ib of L-NMMA and Pembrolizumab

NCT03236935 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Malignant Melanoma
Head and Neck Squamous Cell Carcinoma
Classical Hodgkin Lymphoma
Urothelial Carcinoma Bladder
DNA Repair-Deficiency Disorders

Interventions

DRUG: L-NMMA
DRUG: Pembrolizumab

Sponsor

The Methodist Hospital Research Institute